Israel-based, biopharmaceutical company Kitov Pharmaceuticals has reported positive data following the successful completion of its Phase III trial of combination drug KIT-302 to improve renal function.

KIT-302 is a combination of the US Food and Drug Administration (FDA) approved drug celecoxib (Celebrex), which treats pain triggered by osteoarthritis, and another FDA-approved drug amlodipine besylate, which treats hypertension.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The double-blind, placebo-controlled Phase III trial was intended to quantify the decrease of hypertension in patients administered with KIT-302.

The trial included four groups of 26 to 49 patients each, with a total of 152 patients and was performed in the UK. Each patient was treated over duration of two weeks.

"The company noted that the final results have exhibited a greater rate of reduction in daytime systolic blood pressure after being treated with KIT-302."

Group I was treated with KIT-302, group II was only treated with amlodipine besylate, while group III was only treated with celecoxib and group IV was treated with a double placebo.

The trial was primarily focused on demonstrating the capability of the combination of the two KIT-302 components, administered to Group One, in reducing daytime systolic blood pressure by at least 50% of the reduction in blood pressure achieved within patients in Group Two, who were only treated with amlodipine besylate.

The company noted that the final results have exhibited a greater rate of reduction in daytime systolic blood pressure after being treated with KIT-302.

Furthermore, analysis of the Phase III clinical trial data has also demonstrated the ability of the combination drug KIT-302 in reducing plasma levels of creatinine, thereby improving the renal function, which is affected by nonsteroidal anti-inflammatory drugs (NSAIDs).

Kitov chief medical officer Dr Paul Waymack said: "We are very pleased with the outcome of the renal function analysis.

"We believe it demonstrates that, in addition to addressing hypertension side effects caused by celecoxib, KIT-302 also addresses fluid retention resulting from amlodipine: a known side effect caused by calcium channel blockers."

According to Kitov CEO Isaac Israel, the company is planning to conduct another clinical trial for a scientific validation of the renal benefits rendered by KIT-302, along with submitting the new drug application (NDA) at the end of this year.